Blue Eagle Lithium
High Times
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 10/23/2018 3:45:54 PM - Followers: 1411 - Board type: Free - Posts Today: 14

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
FDA Calendar
Biotech Buyouts/Premiums

Biotech Acronyms
'Way Back' Archive

Blue Eagle Lithium
High Times
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#221579  Sticky Note IPH.PA +37% on multifaceted AZN I-O collaboration—and equity stake: DewDiligence 10/23/18 01:09:32 PM
#221577  Sticky Note ENTA—EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:46:50 AM
#221558  Sticky Note Nektar Therapeutics plunges as Roche data seen as jbog 10/22/18 04:29:05 PM
#221543  Sticky Note NTGN: If you hadn't already figured it RockRat 10/22/18 12:51:01 PM
#221318  Sticky Note Hi, JL. RVNC's RT002 appears to attenuate diffusion DewDiligence 10/10/18 11:19:46 AM
#220844  Sticky Note Allergan pursuit of longer-acting toxin not a risk jbog 09/14/18 11:13:21 AM
#221584   AMRN. Dew , re their balance sheet . Whalatane 10/23/18 03:45:53 PM
#221583   SELB -33% on (more) phase-2 gout data: DewDiligence 10/23/18 03:36:57 PM
#221582   ENTA—This is the ct.g listing for the phase-2 DewDiligence 10/23/18 02:12:49 PM
#221581   Results as early as July or late as CT 10/23/18 02:01:13 PM
#221580   Addendum re ENTA’s RSV program: DewDiligence 10/23/18 01:54:11 PM
#221579   IPH.PA +37% on multifaceted AZN I-O collaboration—and equity stake: DewDiligence 10/23/18 01:09:32 PM
#221578   PTI bouncing on news deal might get done RockRat 10/23/18 01:04:24 PM
#221577   ENTA—EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:46:50 AM
#221576   "In cancer research, the total efficacy of combination swampboots 10/23/18 10:42:25 AM
#221575   5-day chart looks like a buy if you robtewms 10/23/18 10:12:31 AM
#221574   I don't have an education opinion on ACST. DewDiligence 10/23/18 09:42:58 AM
#221573   I haven’t looked at AMRN’s balance sheet lately. DewDiligence 10/23/18 09:41:30 AM
#221572   Here’s the PR for NVS’s 2011 buyout of DewDiligence 10/23/18 09:37:42 AM
#221571   NEO "[NeoGenomics Signs Definitive Agreement to Acquire Genoptix/i] apljack 10/23/18 08:47:52 AM
#221570   Any thoughts on acst? ronpopeil 10/22/18 08:21:04 PM
#221569   so why hasn't Amarin dilute yet? it has linhdtu 10/22/18 08:18:25 PM
#221568   Friday morning's BLRX PR was a harbinger! DewDiligence 10/22/18 07:10:30 PM
#221567   IMGN—(-16%)—was not of the of exceptions to #msg-144374988: DewDiligence 10/22/18 07:07:46 PM
#221566   DVAX—(+11%)—was one of the few exceptions: DewDiligence 10/22/18 06:55:04 PM
#221565   SLS -14% on Neuvax TNBC data at ESMO—stock DewDiligence 10/22/18 06:32:47 PM
#221564   KURA recovered a little to close -19%. Did DewDiligence 10/22/18 06:27:50 PM
#221563   $MRZM $1.60 pps - recently Acquired Protease love your neighbor 10/22/18 06:05:27 PM
#221561   NTGN—I concur with the viewpoint in your Twitter DewDiligence 10/22/18 05:04:23 PM
#221560   What were they waiting for? You gotta strike DewDiligence 10/22/18 04:39:43 PM
#221559   PTI a bit slow by the standards of RockRat 10/22/18 04:37:40 PM
#221558   Nektar Therapeutics plunges as Roche data seen as jbog 10/22/18 04:29:05 PM
#221557   NKTR—...the awareness that anyone can work on a DewDiligence 10/22/18 04:00:30 PM
#221556   sorry, I should read this forum in a dangerM 10/22/18 03:55:35 PM
#221554   …NKTR has a collaboration with SNDX (where they DewDiligence 10/22/18 03:52:58 PM
#221553   ... or RO6874281 (IL2-FAP fusion protein) at ESMO dangerM 10/22/18 03:52:00 PM
#221552   I saw someone tweet something about Roches IL-2 ghmm 10/22/18 02:44:04 PM
#221551   True. Unlike many odd-looking clinical results, there's a DewDiligence 10/22/18 01:50:53 PM
#221550   Keytruda monotherapy bests chemo in OS for PD-L1+ dewophile 10/22/18 01:48:10 PM
#221549   ADRO -34% in sympathy with MRK’s weak results DewDiligence 10/22/18 01:28:13 PM
#221548   MRK—Keytruda data in first-line H&N cancer from KEYNOTE-048 study: DewDiligence 10/22/18 01:19:13 PM
#221547   Yes, that too (eom). DewDiligence 10/22/18 01:05:30 PM
#221546   It seems the Bavencio + axitinib data in dewophile 10/22/18 01:02:12 PM
#221545   By and large, ESMO—>disaster for presenting companies. vlad33301 10/22/18 01:00:09 PM
#221543   NTGN: If you hadn't already figured it RockRat 10/22/18 12:51:01 PM
#221542   AVEO -9% on ESMO data: DewDiligence 10/22/18 11:46:57 AM
#221541   LPTX -10% on ESMO data: DewDiligence 10/22/18 11:43:46 AM
#221540   NCNA -8% on ESMO data: DewDiligence 10/22/18 11:41:27 AM
#221539   By and large, ESMO—>disaster for presenting companies. DewDiligence 10/22/18 11:39:23 AM
#221538   CTMX -8% on ESMO data: DewDiligence 10/22/18 11:38:52 AM
#221537   MRTX -17% on Sitravatinib mono/combo data at ESMO: DewDiligence 10/22/18 11:34:42 AM
#221536   BMY -5% on TMB mess—and 3-month delay in DewDiligence 10/22/18 11:26:42 AM
#221535   NKTR -16%—likely related to the discussion in the DewDiligence 10/22/18 11:23:19 AM
#221534   SNDX -20% on no news—sell-off could be related DewDiligence 10/22/18 11:21:27 AM
#221533   EPZM -7% on phase-2 Tazemetostat data in sarcoma, DewDiligence 10/22/18 11:14:30 AM
#221532   NTGN -15% on phase-1 NEO-PV-1 data at ESMO: DewDiligence 10/22/18 11:03:20 AM
PostSubject